T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Publication
, Journal Article
Horwitz, SM; Ansell, S; Ai, WZ; Barnes, J; Barta, SK; Brammer, J; Clemens, MW; Dogan, A; Foss, F; Ghione, P; Goodman, AM; Guitart, J; Kim, YH ...
Published in: J Natl Compr Canc Netw
March 2022
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma, anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma, anaplastic lymphoma kinase-negative, and enteropathy-associated T-cell lymphoma. This discussion section focuses on the diagnosis and treatment of PTCLs as outlined in the NCCN Guidelines for T-Cell Lymphomas.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
March 2022
Volume
20
Issue
3
Start / End Page
285 / 308
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Lymphoma, T-Cell, Peripheral
- Lymphoma, T-Cell
- Immunoblastic Lymphadenopathy
- Humans
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Horwitz, S. M., Ansell, S., Ai, W. Z., Barnes, J., Barta, S. K., Brammer, J., … Sundar, H. (2022). T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 20(3), 285–308. https://doi.org/10.6004/jnccn.2022.0015
Horwitz, Steven M., Stephen Ansell, Weiyun Z. Ai, Jeffrey Barnes, Stefan K. Barta, Jonathan Brammer, Mark W. Clemens, et al. “T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 20, no. 3 (March 2022): 285–308. https://doi.org/10.6004/jnccn.2022.0015.
Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, et al. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Mar;20(3):285–308.
Horwitz, Steven M., et al. “T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw, vol. 20, no. 3, Mar. 2022, pp. 285–308. Pubmed, doi:10.6004/jnccn.2022.0015.
Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Mar;20(3):285–308.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
March 2022
Volume
20
Issue
3
Start / End Page
285 / 308
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Lymphoma, T-Cell, Peripheral
- Lymphoma, T-Cell
- Immunoblastic Lymphadenopathy
- Humans
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis